UK Government’s NHS Reform Plan Includes Shift to Value-Based Pricing

Any system of value-based pricing for drugs in the UK will need to consider both short- and long-term economic efficiency and appropriately sustain and reward innovation, the Association of British Pharmaceutical Industries says in response to the Conservative-Liberal Democrat coalition government’s white paper outlining its plan to reform the National Health Service (NHS). The plan calls for moving to a value-based pricing regime when the current Pharmaceutical Price Regulation Scheme expires in 2014.
International Pharmaceutical Regulatory Monitor